IP Library Granted Patent US 10,669,590
Granted Patent B2
US 10,669,590 · App. 16/287,438 · Granted Jun 2, 2020

PIK3CA fusions

Inventors: Ethan G. Cerami (Winchester, MA); Christoph Lengauer (Cambridge, MA); Nicolas Stransky (Charlestown, MA)
Assignee: Blueprint Medicines Corporation
C12Q1/6886A61K31/7088C12N15/1137C12Q1/6806C12Q1/6813C12Q2600/156
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,669,590
App. No.
16/287,438
Granted
Jun 2, 2020
Kind
B2
Abstract

The invention provides PIK3CA (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit alpha) gene fusions, and fragments of those gene fusions. The invention further provides methods of diagnosing and treating diseases or disorders associated with PIK3CA fusions, such as conditions mediated by PIK3CA aberrant expression or activity, or overexpression of PIK3CA.

Claims (9)

1. A method for detecting in a patient a FNDC3B:PIK3CA gene fusion, said method comprising:

a) contacting a biological sample from the patient with an oligonucleotide that hybridizes under stringent conditions to the fusion junction of the FNDC3B:PIK3CA gene fusion, and detecting hybridization between the FNDC3B:PIK3CA fusion and the oligonucleotide; or

b) sequencing or amplifying a portion of a nucleic acid from the patient and detecting the presence of a nucleotide sequence comprising at least the FNDC3B:PIK3CA fusion junction,

wherein the FNDC3B:PIK3CA fusion to be detected comprises SEQ ID NO: 3 or a portion thereof comprising the fusion junction.

2. The method of claim 1 , wherein the patient is suffering from or susceptible to a cancer.

3. The method of claim 2 , wherein the cancer is chosen from breast cancer, uterine cancer, and prostate cancer.

4. The method of claim 3 , wherein the cancer is breast cancer.

5. The method of claim 3 , wherein the cancer is uterine cancer.

6. The method of claim 3 , wherein the cancer is prostate cancer.

Assignments (3)
RELEASE OF SECURITY INTEREST (REEL/FRAME NUMBER 060616/0923) Recorded Jul 23, 2025
From: TAO TALENTS, LLC
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 072193/0847 →
SECURITY INTEREST Recorded Jul 8, 2022
From: BLUEPRINT MEDICINES CORPORATION
To: TAO TALENTS, LLC
Reel/Frame 060616/0923 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 14, 2020
From: STRANSKY, NICOLAS; CERAMI, ETHAN G.; LENGAUER, CHRISTOPH
To: BLUEPRINT MEDICINES CORPORATION
Reel/Frame 051819/0851 →
Continuity (3)
Division 15304656
Provisional Application 61981546 · Apr 18, 2014
Related Publication 20190185942A1 · Jun 20, 2019